Skip to main content
Premium Trial:

Request an Annual Quote

Lee Babiss, Jay Stoerker, John Berriman

Roche has named Lee Babiss to the position of head of Global Pharmaceutical Research.
Babiss, who will step into the role on July 1, will be based at the company’s Basel, Switzerland, headquarters, and will be focused on disease biology areas such as virology, oncology, and others that are ongoing at various Roche facilities.
Babiss currently is vice president of preclinical research, serves on the company’s international research management team, and chairs its biomarker team.
Before joining Roche, Babiss was president of biological sciences and genetics at Glaxo Wellcome.

SensiGen, a developer of gene-based molecular diagnostics, has appointed Jay Stoerker to the position of vice president of product development. In this role, he will oversee commercial development of SensiGen’s pipeline of assays for human papillomavirus, nephrin, lupus, inflammatory bowel disease, and other indications.
Stoerker most recently led technology development at Matritech. Prior to that, he was a post-doctoral fellow at the Institute for Molecular Virology in Erlangen, Germany.

Pronota, a predictive biomarker developer, has appointed John Berriman as chairman. Berriman is currently chairman of Algeta ASA and a member of the board of directors of MicroMet, Ablynx, and Oxxon Therapeutics Holdings. Previously, he was a director of Abingworth Management.

Berriman spent 14 years with Celltech Group and was on the company’s board when it listed on the London Stock Exchange in 1994. He has also served on the boards of Solexa, Chroma Therapeutics, Epigenomics, Alnylam, and XCounter.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.